Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Homo sapiens | hydroxyprostaglandin dehydrogenase 15-(NAD) | Starlite/ChEMBL | No references |
Homo sapiens | RAB9A, member RAS oncogene family | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | ras-related protein Rab-5B | RAB9A, member RAS oncogene family | 201 aa | 165 aa | 30.9 % |
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxyprostaglandin dehydrogenase 15-(NAD) | 266 aa | 216 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0016 | 0.55 | 0.55 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Plasmodium falciparum | DNA repair protein REV1, putative | 0.0007 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0016 | 0.55 | 0.55 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0016 | 0.55 | 0.55 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 1 | 0.5 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 1 | 1 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.0023 | 1 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0023 | 1 | 1 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 1 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 1 | 1 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 1 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 1 | 0.5 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 1 | 1 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0007 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 1 | 0.5 |
Plasmodium vivax | DNA repair protein REV1, putative | 0.0007 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 1 | 1 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0007 | 0 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0016 | 0.55 | 0.55 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 1 | 1 |
Toxoplasma gondii | BRCA1 C Terminus (BRCT) domain-containing protein | 0.0007 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Echinococcus granulosus | dna polymerase eta | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0016 | 0.55 | 0.55 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0023 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 5.6234 um | PUBCHEM_BIOASSAY: qHTS Assay for Rab9 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.5733 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase). (Class of assay: confirmatory) [Related pubchem assays: 2429 (Confirmation qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2407 (Probe Development Summary for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2427 (Thermal Shift Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase))] | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493106, AID493143] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen. (Class of assay: confirmatory) [Related pubchem assays: 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.